Friday, June 21, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

How Will Unhealthy Americans React to COVID-19 Vaccines?

overweight Americans

If you look at the human clinical trials that have been conducted this year by drug companies developing experimental vaccines for COVID-19, the participants in those trials have all been “healthy adults.” Take, for example, Moderna’s Phase 1 clinical trial for its mRNA-1273 vaccine, which included 45 healthy adults 18 to 55 years old. The same […]

China Administers Unlicensed Experimental COVID-19 Vaccines to Its Citizens

crowed metro station in China

China is the first country in the world to vaccinate its citizens with experimental COVID-19 vaccines that are still undergoing clinical trials. No other country has vaccinated people on such a large scale with experimental COVID-19 vaccines prior to final regulatory approval for general use as China has done with their coronavirus vaccine candidates.1 Chinese […]

A Grade 3 Vaccine-Related Adverse Event is Serious

ill woman with hand on forehead

When Moderna, Inc. announced on May 18, 2020 the results of a Phase 1 human clinical trial for its experimental mRNA-1273 vaccine for COVID-19, the biotechnology company said the vaccine had produced no “serious adverse events” (SAEs) among the 45 people who participated in the trial and that it considered the vaccine to be “generally […]

81 Percent of Clinical Trial Volunteers Suffer Reactions to CanSino Biologics’ COVID-19 Vaccine That Uses HEK293 Human Fetal Cell Lines

ill woman with hand on forehead

An experimental vaccine for COVID-19 is being developed by CanSino Biologics, Inc. of Tianjin, China, in partnership with China’s Academy of Military Medical Sciences’ Institute of Biotechnology. A Phase 1 human clinical trial of the COVID-19 vaccine (adenovirus type-5 Ad5-nCoV) has been completed in China involving 108 healthy adults, ranging in age from 45–60 years […]

GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells with Squalene Adjuvant

army worms crawling on branch

Story Highlights GlaxoSmithKline and Sanofi Pasteur are partnering to develop an experimental COVID-19 vaccine. The two global vaccine manufacturers are using existing recombinant DNA vaccine technology and a squalene adjuvant for their COVID-19 vaccine. Clinical trials are scheduled to begin in the second half of 2020 and, if successful, the vaccine will be available in […]

Search in Site

To search in site, type your keyword and hit enter